Pooja SirDeshpande

Pooja SirDeshpande

Auto-generated profile, based on publicly available information

Pooja SirDeshpande

Endocrinology, Diabetes and Metabolism, London Northwest University Healthcare NHS Trust, London, GBR

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Journal Of Neuroradiology
Verified
Journal Article
Closed access
LLLakshmi Leishangthem
Lakshmi Leishangthem
PSPooja SirDeshpande
Pooja SirDeshpande
DDDharti Dua
Dharti Dua
SSSudhakar R. Satti
Sudhakar R. Satti

1 June 2019 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
SPSmit Patel
Smit Patel
PSPooja SirDeshpande
Pooja SirDeshpande
RDRupak Desai
Rupak Desai
NDNinad Desai
Ninad Desai
HMHemanshi Mistry
Hemanshi Mistry
NGNeeta Garg
Neeta Garg

8 December 2025 in Cureus
Verified
Journal Article
Open access
PSPooja SirDeshpande
Pooja SirDeshpande
SHSoorya Bavikeri Shivakumara Hegde
Soorya Bavikeri Shivakumara Hegde
HAHassan Akhtar
Hassan Akhtar
With an objective to review the clinical presentation, diagnosis, and management of immune checkpoint inhibitor (ICPi)-associated hypophysitis and pituitary dysfunction, we conducted a systematic review of 84 studies (2005-2025) involving 7,259 patients evaluated pituitary immune-related adverse events (irAEs) linked to CTLA-4 inhibitors, programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors, and combination therapies. Data included ICPi type, demographics, cancer type, treatment duration, imaging, pituitary dysfunction, symptoms and management.